innovation & industrial partnerships

Owned and operated as a joint venture by a consortium of Canadian universities via a contribution through the National Research Council Canada Propriété d’un consortium d’universités canadiennes, géré en co-entreprise à partir d’une contribution administrée par le Conseil national de recherches Canada

Canada’s national laboratory for particle and nuclear physics Laboratoire national canadien pour la recherche en physique nucléaire

et en physique des particules

Accelerating Science for Canada Un accélérateur de la démarche scientifique canadienne

Innovation & Industrial Partnerships

International Peer Review

November 14, 2013

Jim Hanlon CEO / CAO

Head, Business & Administration Division President & CEO, Advanced Applied Physics Solutions Inc.

Q 6: How appropriate are TRIUMF’s activities related to technology transfer and commercialization? How effective have they been in enabling the Canadian industry to become more competitive?

Technology Transfer & Commercialization

November 14, 2013 IPR - Innovation & Industrial Partnerships 2

Staffing: •  Head •  IP & Contracts Manager •  Co-op student (s)

Business Managed: •  Licences (2) Nordion, D-Pace •  IP proposals •  Patents

Technology Transfer – ca. 2007


Federal Government establishes NCE CECR program •  TRIUMF applies & awarded $15M (2008) •  Establishes Advanced Applied Physics Solutions Inc. (AAPS)

•  Tech Transfer staff move over to run company •  TRIUMF patent portfolio transferred to AAPS •  TRIUMF maintains current technology licences •  TRIUMF Tech Transfer managed from Director’s office

Technology Transfer 2007 – 2012


Technology Transfer 2013


CECR Renewal Process 2012 - Successful

Results: •  Extension to March 31, 2017 •  Adequate funds to March 31, 2016

Head Business & Administration Division / President & CEO •  Operates under umbrella of TRIUMF •  Aligns with TRIUMF goals & priorities •  Less ambiguity

Relationship to TRIUMF (supported - TRIUMF / AAPS Boards) •  Continue as non pro#t TRIUMF company •  Responsible for commercialization

AAPS Board of Directors (proposed) •  TRIUMF Board - Innovations & Industrial Partnerships Committee •  Review Board membership

TRIUMF Five Year Plan (2015 – 2020) •  Product Development Manager to identify commercial opportunities from TRIUMF •  AAPS is the conduit for TRIUMF commercialization

CECR funding available to March 31, 2017

•  Goal # 1 – AAPS must be sustainable by March 31, 2016

•  Goal # 2 – Double commercial revenue (over #ve-years)

•  Goal # 3 – Increase annual economic impact by $50M

AAPS = TRIUMF’s Commercial Activities

AAPS Operations


AAPS is a non-pro#t TRIUMF company dedicated to maximizing the economic impact of TRIUMF’s research and development activities for Canada

•  TRIUMF has an exclusive and inclusive relationship with AAPS for all of its interactions with the private sector

•  AAPS is consistently involved, consulted, and available •  AAPS manages industrial access to TRIUMF technology and know-how •  TRIUMF’s partners are encouraged to consider AAPS as a partner or vehicle for ful#lling

their commercialization objectives

•  AAPS provides needed value to TRIUMF by •  Accumulating talent and expertise with a business focus •  Leveraging HQP talent within TRIUMF to advance commercialization efforts •  Making future cash contributions to TRIUMF’s commercial revenue stream •  Taking on commercial activities that would jeopardize TRIUMF’s charitable tax status

and/or increase risks to its Members

What is AAPS?


AAPS – TRIUMF’s technology transfer company

•  Limited liability to TRIUMF member universities

•  Eligibility for WED / IRAP & other grants for commercialization

•  Leverage commercial opportunities with seed capital

•  Core competency focus on commercialization

•  TRIUMF & partners develop generalized “platform” technologies, guided by conversations with the market and AAPS

•  AAPS identi#es opportunities for platform technologies to address market problems

•  AAPS recruits industrial partner(s) to join forces in developing & commercializing a product using TRIUMF/partner technology to meet the speci#c market need

Direct Bene!ts to TRIUMF


AAPS provides direct, tangible bene#t to TRIUMF in multiple ways

•  Helps ful#ll TRIUMF’s mandate to exploit commercial opportunities from its research & development activities

•  In-kind hardware contributions (e.g., HRS magnet for CANREB, $1.2M)

•  In-kind labour contributions (e.g., Project management)

•  Cash payment for TRIUMF services (e.g., Machine Shop / Design Office)

•  Future cash deposits into TRIUMF commercial-revenue accounts

Direct Bene!ts to TRIUMF


AAPS - Role

10

Pro

duct

Dev

elop

men

t Man

ager

0.0

10.0

20.0

30.0

40.0

50.0

60.0

70.0

80.0

90.0

100.0

non-NRC

NRC

TRIUMF Resource Usage by AREA (2013) Combined Operations and Projects


FTE

s

29 FTEs

Project Institution Company Investment Outcome

High Resolution Separator

AAPS / TRIUMF ACSI $ 1.2 M (AAPS) $ .4 M (ACSI)

$2.5 M magnet Licence agreement

IKOMED AAPS Private Investment

$ .9 M (AAPS) $ 2.0 M (private)

Loan repayment + int / or Licence agreement

Medical isotopes ITAP – NRCan ARTMS $ .250 M (AAPS) Supply Tc-99m +

Muon detectors AAPS / WED / IRAP CRM $ 2.2 M (AAPS) $ 1.8 M (WED) $ .150 M (IRAP)

Loan repayment Licence agreement

CVD / DLC #lms TRIUMF / AAPS Micromatter $ ~ .5 M (AAPS) Equity Sale of Company

Neutron Well Logging AAPS / GPN Newco $ .4 M (AAPS) $ .8 M (GPN)

Equity Licence Agreement

PIF & NIF TRIUMF / AAPS Service Value added $ ~ . 300 M / year

Royalties TRIUMF Nordion Licence agreement $ ~ 1.25M / year

Royalties TRIUMF D-Pace Licence agreement $ ~ 25K / year

Cryomodules AAPS / TRIUMF PAVAC $ .150 M (AAPS) Licence Agreement

Ion source development

AAPS / TRIUMF TBA $ .150 M (AAPS) WFO Licence Agreement

Patents AAPS / TRIUMF AAPS $ 1.2 M (AAPS) Maintenance over 5 years

Current Portfolio - Outcome

12

Project Institution Company Investment Impact



2 FTEs

IKOMED AAPS Private Investment

$ .9 M (AAPS) $ 2.0 M (private)

7 FTEs

Medical isotopes ITAP – NRCan ARTMS $ .250 M (AAPS) 1.5 FTEs


3 FTEs

CVD / DLC #lms TRIUMF / AAPS Micromatter $ ~ .5 M (AAPS) 4 FTEs


2 FTEs

PIF & NIF TRIUMF / AAPS Service Value added

Royalties TRIUMF Nordion Licence agreement

Royalties TRIUMF D-Pace Licence agreement

Cryomodules AAPS / TRIUMF PAVAC $ .150 M (AAPS) 1 FTE

Ion source development

AAPS / TRIUMF TBA $ .150 M (AAPS) 1 FTE

Overhead AAPS / TRIUMF 4.5 FTEs

Total FTE 26 FTEs

Current Portfolio – Direct Impacts

13

Project Institution Company Investment Impact



Increased jobs Canadian technology sold worldwide

IKOMED AAPS Private Investment $ .9 M (AAPS) $ 2.0 M (private)

Reduced radiation exposure to doctors & patients

Medical isotopes ITAP – NRCan ARTMS $ .250 M (AAPS) Accelerator based medical isotopes – eliminate cost of reactor and radioactive waste


Unique prospecting technique that may lead to major environmental bene#ts

CVD / DLC #lms TRIUMF / AAPS Micromatter $ ~ .5 M (AAPS) Leverage TRIUMF competency


Environmental - cleaner oil extraction

PIF & NIF TRIUMF / AAPS Service Value added Increase performance & cost efficiency in market

Royalties TRIUMF Nordion Licence agreement Health bene#ts worldwide from Canadian technology

Royalties TRIUMF D-Pace Licence agreement Increased jobs / Canadian technology sold worldwide

Cryomodules AAPS / TRIUMF PAVAC $ .150 M (AAPS) Increased jobs / Canadian technology sold worldwide

Ion source development AAPS / TRIUMF TBA $ .150 M (AAPS) Improving efficiency of cyclotrons to produce medical isotopes

Overhead AAPS / TRIUMF HQP employment

Current Portfolio – Indirect Impacts

14

•  Five Years •  AAPS will continue as a stand-alone non-pro#t company •  Commercial activities will contribute >3% of TRIUMF

operating budget by 2020

•  Ten Years •  Commercial activities will contribute >5% of TRIUMF

operating budget by 2025

The Future


Commercial Revenue to TRIUMF / AAPS

$-

$500,000

$1,000,000

$1,500,000

$2,000,000

$2,500,000

$3,000,000

$3,500,000

2015 2016 2017 2018 2019 2020

Nordion

Micromatter

Well Logging

HRS

Tc-99m

PAVAC

Ikomed

Geotom

PIF&NIF


Commercial Revenue to TRIUMF / AAPS

$-

$200,000

$400,000

$600,000

$800,000

$1,000,000

$1,200,000

$1,400,000

$1,600,000

$1,800,000

2015 2016 2017 2018 2019 2020

TRIUMF

AAPS


Direct Economic Impact Industrial Partnerships

$-

$10,000,000

$20,000,000

$30,000,000

$40,000,000

$50,000,000

$60,000,000

2015 2016 2017 2018 2019 2020

Nordion

Micromatter

Well Logging

HRS

Tc-99m

PAVAC

Ikomed

Geotom

PIF&NIF


innovation & industrial partnerships

Documents